BIOTECH AND PHARMANEWS

Paxlovid COVID Rebound: No Evidence for More Treatment, Says CDC

Bibliometric Details: Issue No: 5 | Issue Month:May | Issue Year:2022

No proof exists to augment an additional route of medication in patients with COVID-19 who trip a recurrence in sickness after taking nirmatrelvir/ritonavir (Paxlovid), the CDC mentioned on Tuesday.

In a Smartly being Advisory, the company reiterated that patient monitoring is the most acceptable medication, and clinicians must silent expose patients with symptom rebound to re-isolate for on the least 5 days, as smartly as resolve display of being evaluated by a scientific educated if their signs aggravate. They must silent additionally wear a screen in public for a total of 10 days following rebound signs.

Related Articles

Content Protection by DMCA.com

Back to top button